# Mct Oil Cognitive Performance Randomized Trial: What the Evidence Says
Canonical: https://www.migaku.app/guides/mct-oil-cognitive-performance-randomized-trial-evidence-review
Category: evidence-review
Summary: Mct Oil Cognitive Performance Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first p
Last reviewed: 2026-08-13
Reviewed by: Migaku Evidence Review
# Mct Oil Cognitive Performance Randomized Trial: What the Evidence Says

## Quick Answer

Mct Oil Cognitive Performance Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, so conclusions should be framed as evidence-aware guidance rather than medical advice.

## Key Takeaways

- This page is generated only from sources stored in the Migaku evidence knowledge base.
- Current evidence mix: 1 systematic review, 1 preclinical study.
- Claims should be interpreted with the source type, study design, population, and publication date in mind.
- This article is educational and does not replace care from a qualified clinician.

## Evidence Map

| Source | Evidence type | Level | Date | Identifier |
| --- | --- | ---: | --- | --- |
| The effect of exogenous ketone bodies on cognition across health and disease: a systematic review and meta-analysis | systematic review | 1 | 2026-04-15 | 10.3389/fnut.2026.1802531 |
| Ketogenic diet as a therapeutic strategy for neurodegenerative diseases: from mechanisms to translational challenges | preclinical study | 4 | 2026-05-25 | 10.1186/s40035-026-00557-1 |

## What The Sources Report

- In addition to the reduced quality of life and wellbeing for the patient, ADRD also imposes a cost on society through the significant financial burden of patient care. [Bonnechère Bruno (2026); evidence level 1]
- Mitochondrial dysfunction plays a central role, leading to impaired oxidative phosphorylation, reduced adenosine triphosphate (ATP) generation, and increased oxidative stress, all contributing to cellular damage and death. [Salgueiro Ana Margarida (2026); evidence level 4]
- In addition, growing evidence suggests that the gut-brain axis disruption, such as changes in microbiota composition and increased intestinal permeability, can contribute to neuroinflammation. [Salgueiro Ana Margarida (2026); evidence level 4]

## How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

## Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. For mct oil cognitive performance randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

## Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

## References

- Bonnechère Bruno (2026). The effect of exogenous ketone bodies on cognition across health and disease: a systematic review and meta-analysis. DOI: 10.3389/fnut.2026.1802531. PMCID: PMC13127162. PMID: 42063954. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13127162/
- Salgueiro Ana Margarida (2026). Ketogenic diet as a therapeutic strategy for neurodegenerative diseases: from mechanisms to translational challenges. DOI: 10.1186/s40035-026-00557-1. PMCID: PMC13200306. PMID: 42186042. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13200306/

## Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.